目的 探究氨酚曲马多片联合普瑞巴林胶囊治疗癌性神经病理性疼痛的临床疗效。方法 选取2015年4月—2017年4月郑州大学附属郑州中心医院收治的癌性神经病理性疼痛患者150例为研究对象，所有患者随机分为普瑞巴林组、氨酚曲马多组和联合治疗组，每组各50例。普瑞巴林组口服普瑞巴林胶囊，75 mg/次，2次/d；氨酚曲马多组口服氨酚曲马多片，100 mg/次，1次/d；联合治疗组口服普瑞巴林胶囊和氨酚曲马多片，用法同上。所有患者均连续治疗4周。观察两组的临床疗效，比较两组的疼痛数字（NRS）评分、生活质量（QOL）评分和睡眠质量（MOS）评分。结果 治疗后，普瑞巴林组、氨酚曲马多组、联合治疗组疼痛总缓解率分别为62.00%、64.00%、82.00%，联合治疗组与普瑞巴林组、氨酚曲马多组比较差异具有统计学意义（P < 0.05）。治疗后，3组NRS评分均显著降低，同组治疗前后比较差异具有统计学意义（P < 0.05）；且联合治疗组NRS评分明显低于普瑞巴林组、氨酚曲马多组，两组比较差异具有统计学意义（P < 0.05）。治疗后，3组QOL评分均显著降低，同组治疗前后比较差异具有统计学意义（P < 0.05）；且联合治疗组QOL评分明显低于普瑞巴林组、氨酚曲马多组，两组比较差异具有统计学意义（P < 0.05）。治疗后，普瑞巴林组、联合治疗组睡眠干扰（SLPD）、睡眠量（SLPQ）评分显著降低，睡眠充足度（SLPA）评分显著升高，同组治疗前后比较差异具有统计学意义（P < 0.05）；且联合治疗组这些观察指标的改善程度明显优于普瑞巴林组、氨酚曲马多组，3组比较差异具有统计学意义（P < 0.05）。结论 氨酚曲马多片联合普瑞巴林胶囊治疗癌性神经病理性疼痛具有较好的临床疗效，可缓解患者癌性疼痛，改善患者生活质量和睡眠质量，安全性较好，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Paracetamol and Tramadol Hydrochloride Tablets combined with Pregabalin Capsules in treatment of cancerous neuropathic pain. Methods Patients (150 cases) with cancerous neuropathic pain in Zhengzhou Central Hospital Affiliated to Zhengzhou University from April 2015 to April 2017 were randomly divided into pregabalin, paracetamol and tramadol, and combined treatment groups, and each group had 50 cases. Patients in the pregabalin group were po administered with Pregabalin Capsules, 75 mg/time, twice daily. Patients in the paracetamol and tramadol group were po administered with Paracetamol and Tramadol Hydrochloride Tablets, 100 mg/time, once daily. Patients in the combined treatment group were given Pregabalin Capsules and Paracetamol and Tramadol Hydrochloride Tablets, usage as above. Patients in three groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and NRS scores, QOL scores, and MOS scores in three groups were compared. Results After treatment, the pain relief rates in the pregabalin, paracetamol and tramadol, and combined treatment groups were 62.00%, 64.00%, and 82.00%, respectively, and there was difference between combined treatment group with pregabalin group, paracetamol and tramadol group (P < 0.05). After treatment, the NRS scores in three groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the NRS score in the combined treatment group were significantly lower than that in the pregabalin group and the paracetamol and tramadol group, with significant difference between two groups (P < 0.05). After treatment, the QOL scores in three groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the QOL score in the combined treatment group were significantly lower than that in the pregabalin group and the paracetamol and tramadol group, with significant difference between two groups (P < 0.05). After treatment, the SLPD scores and SLPQ scores in the pregabalin group and the combined treatment group were significantly decreased, but the SLPA scores in the pregabalin group and the combined treatment group were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the combined treatment group were significantly better than those in the pregabalin group and the paracetamol and tramadol group, with significant difference between two groups (P < 0.05). Conclusion Paracetamol and Tramadol Hydrochloride Tablets combined with Pregabalin Capsules has clinical curative effect in treatment of cancerous neuropathic pain, can relieve the cancer pain, improve the quality of life and the quality of sleep, which has a certain clinical application value.